

Zeltia

H115 results

Yondelis approvals in US and Japan pending

Pharma & biotech

Zeltia is approaching a number of significant catalysts, with approval decisions for Yondelis in the US and Japan due before the end of the year, and Phase III data for Aplidin expected early in the New Year. Plans to seek an IPO in the US in H216 following the group's restructure (through a reverse merger whereby its PharmaMar division absorbed the parent company, Zeltia) could strengthen its financial and commercial abilities. We maintain our valuation of €1.03bn or €4.65 per share, ahead of these catalysts.

25 August 2015

Price €3.29

Market cap €731m

US\$1.10/€

Net debt (€m) at 30 June 2015 61.7

Shares in issue 222.2m

Free float 73.3%

Code ZEL

Primary exchange Madrid

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs (18.4) (17.7) 16.5

Rel (local) (5.4) (2.5) 25.4

52-week high/low €4.32 €2.38

Business description

Zeltia is a Spanish biopharmaceutical group with a core focus on the development of marine-based drugs for cancer. Yondelis is approved in the EU and partnered with Janssen (J&J) in the US and Taiho in Japan. The group also has subsidiaries commercialising and developing consumer chemicals, molecular diagnostics and RNAi.

Next events

Yondelis: PDUFA review in STS October 2015

Yondelis: Japan approval in STS Q415

Aplidin: Phase III ADMYRE data in multiple myeloma Q116

Potential US IPO H216

Analysts

Christian Glennie +44 (0)20 3077 5727

Lala Gregorek +44 (0)20 3077 5700

Dr Dennis Hulme +61 (0)2 9258 1161

healthcare@edisongroup.com
[Edison profile page](#)

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/13	141.8	15.6	0.06	0.0	54.8	N/A
12/14	149.7	16.3	0.07	0.0	47.0	N/A
12/15e	163.1	15.2	0.06	0.0	54.8	N/A
12/16e	198.2	35.9	0.15	0.0	21.9	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items.

Yondelis: Approvals pending

Key near-term catalysts for Zeltia are the pending approval decisions in major markets for Yondelis, which is already marketed in 80 countries. The PDUFA date is 24 October for a decision on US FDA approval as a second-line treatment for soft tissue sarcoma (STS), while a decision on the same indication in Japan could be announced any time from mid-September onwards. Approvals could significantly boost revenues through milestones and royalties from its partners (Janssen in the US, Taiho in Japan). Another significant potential catalyst is results from the Phase III study of Aplidin in multiple myeloma, which are due in Q116.

PM01183: Phase III begun in ovarian, pending in lung

PM01183 (a Yondelis follow-on) has generated highly encouraging clinical data in ovarian cancer and SCLC, which was presented at ASCO in June. A Phase III trial in platinum-resistant ovarian cancer was initiated in June. The company is finalising the design of a proposed Phase III trial in small cell lung cancer (SCLC) after positive data from a Phase Ib study; the Phase III is expected to start Q415.

H115: Sales revenue up, milestones down

H115 net revenues rose by 8% to €84.4m. EBITDA was 57% lower at €9.5m, reflecting the smaller US\$10m Yondelis milestone received from Janssen, compared with US\$25m in H114, as was expected in line with the deal terms. With Yondelis approval milestones worth \$20m (\$10m for US, \$10m for Japan) potentially receivable in the second half, we forecast FY15e EBITDA to be €27.0m, 5% ahead of FY14.

Valuation: Unchanged at €4.65 per share

Our valuation is unchanged at €1.03bn (€4.65/share), with increased R&D and capex spending offset by the roll-forward of the DCF model. We see significant potential upside from Yondelis approvals in the near term, and Aplidin data in Q116.

Reverse merger brings oncology portfolio to the fore

Historically, Zeltia was a Spanish biopharma/chemicals group comprising a number of subsidiaries: PharmaMar (oncology drug development and commercialisation), Genómica (molecular diagnostics), Sylentis (RNAi gene silencing technology development) and two consumer chemicals companies, Zelnova and Xylazel.

A shareholders' meeting in June 2015 approved a reverse merger whereby the oncology division PharmaMar absorbed Zeltia, with one PharmaMar share exchanged for each Zeltia share. Friday 30 October will be the last trading day for Zeltia shares. PharmaMar shares are expected to begin trading on Monday 2 November on the same official markets on which Zeltia shares are currently listed (primarily Bolsa de Madrid – BME).

One of the key outcomes of the corporate restructure is the intention to seek a US IPO under the PharmaMar name, possibly in H216. If the US listing occurs it could strengthen the company's financial position, and potentially also enable the group to expand its US operations. Janssen (J&J) is already a key partner for Yondelis in the US, but there would be scope to build a US business commercialising pipeline oncology products, most likely PM01183, but possibly also Aplidin, if pivotal trials are successful.

Yondelis – two potential approvals in H215

The PDUFA date for the FDA review for Janssen's (J&J) NDA application to market Yondelis in the US as a second-line treatment for soft tissue sarcoma (STS) is 24 October. In July Zeltia announced that it had successfully cleared another hurdle in the approval process, with the manufacturing facility for the Yondelis active ingredient trabectedin having passed FDA inspection as acceptable for supply to the US market.

FDA approval would trigger a \$10m milestone payment from J&J. Zeltia will also receive tiered double-digit royalties on net US sales from J&J, and in our model we apply an effective blended annual royalty rate of 15%. J&J is also conducting a pivotal Phase III trial with Yondelis in third-line ovarian cancer, although the study is not expected to read-out until 2018.

Partner Taiho Pharmaceutical filed for approval in Japan in January 2015 for the use of Yondelis to treat advanced STS. With orphan drug designation in Japan, a decision could be made as early as September 2015. Zeltia would receive a \$10m milestone on Japanese approval.

ASCO data highlight PFS benefit of Yondelis in STS

Janssen presented data at ASCO 2015 from the interim analysis of the Phase III trial of Yondelis in second-line treatment of STS. These data were a key component of the NDA submission in October 2014.

Exhibit 1 shows that treatment with Yondelis reduced the risk of disease progression or death (PFS) by 45% compared to dacarbazine (hazard ratio (HR) 0.55, $p < 0.0001$). Median progression-free survival (PFS) was 4.2 months for Yondelis-treated patients vs 1.5 months for dacarbazine.

At the interim analysis the trial had not yet met the primary endpoint for overall survival (OS). The OS data are not yet mature, with 64% of patients censored (non-informative) in the analysis. Nonetheless, there was a numerical trend consistent with a 13% reduction in the risk of death in patients treated with Yondelis (HR 0.87, $P = 0.37$), although this trend was not reflected in the median OS, which favoured dacarbazine by two weeks (12.4 months for Yondelis vs 12.9 months for dacarbazine). The study is ongoing to determine the final OS results.

Safety findings were consistent with the known toxicity profiles of both drugs. The most common grade 3-4 toxicities for Yondelis vs dacarbazine were neutropenia (40% vs 25%) and transient

increases in liver enzymes (ALT, 29% vs 1%). Drug related deaths occurred in 2.1% of patients in the Yondelis group vs none on dacarbazine.

Encouragingly, in February the FDA granted priority review status to Janssen's NDA application to market Yondelis in the US. Priority review is a designation for a drug that treats a serious condition and may offer major advances in treatment when compared to existing options. The FDA's decision to grant priority review status to Yondelis reflects the fact that there are no effective treatment options for patients who have failed treatment with doxorubicin and ifosfamide.

The FDA will be assessing whether the 2.7 month increase in PFS leads to a better life for patients, when weighed up against the known toxic side effects. We maintain our assumption that there is a 90% likelihood that the FDA decision in October will be positive.

Exhibit 1: Interim data from Yondelis Phase III in STS show PFS benefit				
	Hazard ratio	p	Median (mths) or %	
			Yondelis	Dacarbazine
Secondary endpoints (mature data)				
Progression-free survival	0.55	<0.0001	4.2	1.5
Time to progression	0.52	<0.0001	4.2	1.5
Overall response rate	N/A	0.33	9.9%	6.9%
Duration of response	0.47	0.14	6.5	4.2
Primary endpoint interim analysis				
Overall survival	0.87	0.37	12.4	12.9
Additional analysis not listed as secondary endpoint				
Clinical benefit rate (CR+PR+SD≥18wks)	N/A	0.0002	34.2%	18.5%

Source: Demetri et al ASCO [abstract](#) June 2015, Edison Investment Research. Note: CR = complete response; PR = partial response; SD≥18wks = stable disease for at least 18 weeks.

PM01183 – ovarian cancer Phase III underway, lung next

PM01183 is effectively a second-generation compound of Yondelis, with activity in similar (ovarian cancer) and new indications (SCLC, NSCLC, breast cancer). The compound has been optimised to improve the PK profile, such that PM01183 can be given at 4x the tolerated dose level of Yondelis and offers administration advantages. PM01183 can be administered in a one-hour infusion using a peripheral intravenous catheter, compared to a 24-hour infusion with Yondelis via a central catheter.

On 29 June, Zeltia initiated a Phase III trial of PM01183 as a monotherapy in platinum-resistant ovarian cancer, compared to a control arm with topotecan or liposomal doxorubicin. The randomised open-label trial will enrol 420 women with unresectable platinum resistant ovarian cancer, and will assess whether PM01183 can improve PFS as the primary endpoint. This pivotal study follows encouraging PFS and OS rates in a Phase IIb trial.

Zeltia is currently finalising the design of a pivotal Phase III study in small cell lung cancer (SCLC) after positive data from a Phase Ib study. The proposed Phase III will be a head-to-head study comparing the combination of PM01183 and doxorubicin against topotecan, in relapsed (second-line) SCLC patients. Preliminary results from the Phase Ib study showed that 67% of SCLC patients responded to PM01183 plus doxorubicin, compared to response rates of 20-25% typically seen with standard-of-care drug Topotecan.

Aplidin – ADMYRE fully recruited, results in Q116

Recruitment in the 255-patient Phase III ADMYRE trial of Aplidin in relapsed/refractory multiple myeloma was completed in June. The trial is comparing the effectiveness of the combination of Aplidin plus dexamethasone vs dexamethasone alone. PFS is the primary endpoint (estimated average of five months); an interim analysis in December 2012 reported that at that stage Aplidin was on track to meet the efficacy target of a 60% improvement in PFS. OS (estimated average of nine months) will also be assessed as a secondary endpoint. Results are expected in Q116; if the results are positive, Zeltia plans to file for marketing approval in Europe in 2016.

Zeltia licensed Aplidin marketing rights in certain EU country rights (France, Germany, the UK, Benelux, Ireland, Austria) to Chugai in July 2014; Taiwan rights to TTY Biopharm in July 2015; and Australia and New Zealand rights to Specialised Therapeutics Australia in August 2015. Zeltia retains commercialisation rights in several key European territories, including Spain, Italy and Northern Europe, where we assume it will market Aplidin using its existing sales force. We expect Zeltia to also seek a partner in the US, where the initial approval may be for the ultra-orphan indication immunoblastic T-cell lymphoma (which accounts for 2% of non-Hodgkin's lymphomas).

Valuation

Our sum-of-the-parts DCF model (project-based rNPV for the biopharma business; FCF for the chemicals division to 2025) is unchanged at €1.03bn or €4.65/share (Exhibit 2), with some minor increases in forecast costs offset by the roll forward of the DCF model. We have not made any changes to product development timelines or likelihoods of success.

Notable changes include:

- forecast R&D expenditure increased by 16% in FY16 and 25% in FY17, in light of the Phase III trial of PM01183 in breast cancer having started in Q215, and another Phase III in lung cancer expected to begin before the end of the year; and
- increasing capex in line with the higher run-rate in H115.

Exhibit 2: Zeltia sum-of-the-parts DCF

Product	rNPV (€m)	rNPV/ share (€)	Assumptions
Chemicals business FCF	57.7	0.26	7.5% WACC, 2% growth rate, accounts for 25% of group capex and depreciation and amortisation.
Yondelis (Europe)	752.1	3.38	Second-line STS peak sales of €80m with 35% penetration; third-line ovarian cancer peak sales of €100m with 22% penetration into addressable platinum sensitive market. First potential generics in 2022. 10% WACC
Yondelis (US)	71.0	0.32	STS (second-line) peak sales of \$130m with 90% probability and 2016 launch; peak sales in platinum-sensitive ovarian cancer of \$150m, 65% risk adjustment, 2020 launch; both assume 15% royalty from J&J.
Yondelis (Japan)	49.1	0.22	STS only: peak sales of €130m; 90% success probability; launch 2016; 15% royalty from Taiho.
Yondelis (milestones)	12.0	0.05	Known milestones for H215 only – Janssen: \$10m in for US approval; Taiho: Japan approval. Risk-weighting applied; assumes \$/€ FX rate of 1.10.
Aplidin (multiple myeloma)	140.7	0.63	Global peak sales of \$300m assuming 40% of MM patients ultimately receive fourth-line therapy and 25% penetration; pricing of \$25k in EU with 25% US premium; 65% success probability; launch 2018; sold by Chugai in eight European territories (assume effective royalty of 25%) and direct in other EU regions, assume 25% royalty in US; includes €20m of near-term regulatory milestones out of €30m total. No milestones included for other territories at this stage.
PM01183 (ovarian cancer)	286.8	1.29	Third-line platinum-resistant ovarian cancer: peak sales of €492m with 65% success probability, 2019 launch; sold direct in Europe with 25% royalty in US (post Phase III).
PM01183 (SCLC)	51.9	0.23	Peak sales of \$200m; 50% success probability; launch 2019; 25% royalty (post Phase III).
PM01183 (breast/NSCLC)	32.6	0.15	Combined peak sales of \$500m; 15% success probability; launch 2020; 25% royalty (post Phase III).
Sylentis	5.7	0.03	Cumulative peak sales of \$250m, with 25% probability of success, potential launch 2019, 10% royalty.
Genomica	26.9	0.12	Conservative 2% growth rate.
R&D	(165.2)	(0.74)	12.5% WACC.
SG&A	(180.3)	(0.81)	10% WACC.
Unallocated central costs	(36.1)	(0.16)	10% WACC.
Capex	(9.9)	(0.04)	75% of group capex for biopharma business.
Net cash/(debt)	(61.7)	(0.28)	At end-Q215.
Total	1,033.3	4.65	

Source: Edison Investment Research. Note: WACC of 12.5% used except where indicated otherwise.

With regard to PM01183 and Aplidin, we note that we have maintained our previous assumptions that these products will be out-licensed at some stage. However, we acknowledge that with the new corporate structure, US IPO plans and resulting opportunity to establish a US commercial business, PM01183 (and possibly also Aplidin) could be retained by PharmaMar for self-commercialisation.

This would typically provide greater economic returns on these products (even after the extra investment required), so confirmation of a go-it-alone strategy in the US (and across Europe) would add upside.

Sensitivities

PharmaMar is subject to various sensitivities common to speciality pharmaceutical companies, including potential clinical or regulatory failure or delay, manufacturing and commercialisation risks (launch, uptake, pricing, reimbursement and competition), and reliance on partners for ex-Europe markets. The chemical business is predominantly exposed to economic factors, although raw material costs, environmental/regulatory requirements and external weather conditions may also affect sales or margins.

Key stock-specific sensitivities for the core oncology business include, but are not limited to:

- **Yondelis:** European sales growth; outcome of ongoing US clinical trials; outcome of FDA and Japanese approval decisions in 2015; timing of milestones from partners and sales achieved.
- **Aplidin:** outcome of the ADMYRE trial; development progress in T-cell lymphoma; timing and economics of any additional licensing deal(s).
- **PM01183:** development progress in various indications; deal timing and economics.

Financials

Zeltia's H115 net revenues of €84.4m were up 8% on H114 (€78.2m), with the 12% growth in biopharmaceuticals (FY14: €82.3m vs FY13: €79.1m) much stronger than Consumer Chemicals (up 3%; H115: €37.1m vs H114: €36.1m). H115 net sales of Yondelis (mainly in Europe, reported within biopharma) rose 11.4% to €43.6m, including €3.3m from the sale of raw materials to Janssen; commercial sales of Yondelis (excluding raw materials) rose by 3%. Gross margin in H115 was 71.8% (vs 72.7% in H114). Other revenues of €11.7m were 41% lower than H114 (€19.8m), reflecting the smaller \$10m (€8.8m) Yondelis milestone received from Janssen, compared with US\$25m (€18.3m) in H114. Yondelis approval in the US and Japan could trigger a further ~\$20m (€18m) in milestone payments in H215.

R&D spending, which is predominantly focused on the oncology business, rose 29% to €30.6m (€22.1m in H114). The increase in R&D spending was mainly due to the pivotal registration trial of PM1183 in platinum-resistant ovarian cancer. We forecast R&D spending to total €55m in FY15e and €47m in FY16e. Note that a proportion of this R&D is capitalised (we assume c 10%). Total SG&A expenses were €33.0m in H115 (vs €31.0m in FY13); we forecast SG&A to total €64.3m in FY15 and €66.6m in FY16. EBITDA for the group in H115 was €9.5m, 57% below the €22.1m reported in H114, again reflecting the smaller \$10m Yondelis milestone in the current period; we forecast ~\$20m Yondelis approval milestones in H215e to lead to 5% EBITDA growth to €27.0m in FY15e.

At December 2014 the company had €26m net deferred tax assets, plus additional unrecognised or unallocated deferred tax assets totalling €96m. In view of this, we now forecast a continuing minimal tax charge into FY17 compared with our previous assumption of a 21% tax rate in that year. Slight reductions to forecast earnings and cash flow reflect the R&D expenditure increasing by 16% in FY16 and 25% in FY17 due to PM01183 Phase III clinical trials.

Exhibit 3: Financial summary

	€000s	2012	2013	2014	2015e	2016e	2017e
Year-end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS							
Revenue		138,229	141,824	149,652	163,083	198,233	224,015
Cost of Sales		(39,793)	(37,900)	(40,765)	(44,878)	(47,454)	(50,363)
Gross Profit		98,436	103,924	108,887	118,205	150,779	173,653
R&D Expenses (net of capitalised in-house work)		(36,996)	(38,335)	(46,477)	(55,050)	(48,500)	(46,550)
Sales, General and Administrative Expenses		(62,467)	(61,489)	(60,831)	(64,253)	(66,598)	(69,270)
EBITDA		20,473	23,817	25,704	27,044	47,702	84,716
Operating Profit (before GW and except.)		15,985	20,735	22,096	20,360	41,013	78,682
Intangible Amortisation		(1,418)	(1,779)	(1,859)	(1,092)	(2,119)	(1,950)
Other (milestones and royalties)		23,549	22,858	28,408	30,310	13,258	29,044
Exceptionals		0	0	0	0	0	0
Operating Profit		14,567	18,956	20,237	19,267	38,894	76,732
Net Interest		(5,056)	(5,690)	(5,762)	(5,132)	(5,154)	(5,008)
Other		(85)	535	0	0	0	0
Profit Before Tax (norm)		10,844	15,580	16,334	15,228	35,859	73,673
Profit Before Tax (FRS 3)		9,426	13,801	14,475	14,135	33,740	71,724
Tax		5,048	(1,960)	(1,304)	(1,030)	(1,784)	(2,016)
Deferred tax		0	0	0	0	0	0
Profit After Tax (norm)		15,892	13,620	15,030	14,197	34,075	71,657
Profit After Tax (FRS 3)		14,474	11,841	13,171	13,105	31,956	69,708
Minority interests		2,868	189	20	0	0	0
Discontinued operations		(10,749)	(708)	(76)	0	0	0
Net income (normalised)		18,760	13,809	15,050	14,197	34,075	71,657
Net income (FRS3)		6,593	11,322	13,115	13,105	31,956	69,708
Average Number of Shares Outstanding (m)		220.8	220.2	222.2	222.2	222.2	222.2
EPS - normalised (€)		0.08	0.06	0.07	0.06	0.15	0.32
EPS - FRS 3 (€)		0.03	0.05	0.06	0.06	0.14	0.31
Dividend per share (€)		0.00	0.00	0.00	0.00	0.00	0.00
Gross Margin (%)		71.2%	73.3%	72.8%	72.5%	76.1%	77.5%
EBITDA Margin (%)		14.8%	16.8%	17.2%	16.6%	24.1%	37.8%
Operating Margin (before GW and except.) (%)		11.6%	14.6%	14.8%	12.5%	20.7%	35.1%
BALANCE SHEET							
Fixed Assets		90,614	92,627	98,401	97,385	92,542	89,038
Intangible Assets		22,292	25,138	28,836	29,040	26,920	24,971
Tangible Assets		29,794	27,959	29,218	27,869	25,145	23,590
Other		38,528	39,530	40,347	40,477	40,477	40,477
Current Assets		106,431	95,895	101,916	137,666	176,818	252,326
Stocks		23,502	22,232	24,404	24,591	26,002	27,596
Debtors		41,956	38,630	36,989	40,212	48,879	55,237
Cash		34,428	28,835	35,511	67,004	96,078	163,634
Other		6,545	6,198	5,012	5,859	5,859	5,859
Current Liabilities		(87,355)	(74,058)	(82,626)	(71,138)	(72,482)	(73,970)
Creditors		(32,621)	(32,731)	(38,160)	(30,737)	(32,081)	(33,569)
Short term borrowings		(54,734)	(41,327)	(44,466)	(40,401)	(40,401)	(40,401)
Long Term Liabilities		(73,749)	(65,877)	(58,694)	(81,737)	(82,496)	(83,053)
Long term borrowings		(62,016)	(52,941)	(47,003)	(70,171)	(70,171)	(70,171)
Other long term liabilities		(11,733)	(12,936)	(11,691)	(11,566)	(12,325)	(12,882)
Net Assets		35,941	48,587	58,997	82,176	114,382	184,340
CASH FLOW							
Operating Cash Flow		5,751	15,489	23,475	13,034	39,976	79,061
Net Interest		876	1,057	(1,000)	(2,419)	(5,154)	(5,008)
Tax		(308)	(201)	(366)	(1,030)	(1,784)	(2,016)
Capex		(2,029)	(2,095)	(10,179)	(6,541)	(3,965)	(4,480)
Acquisitions/disposals		0	447	4	0	0	0
Financing		1,368	0	0	9,050	0	0
Other		0	0	0	0	0	0
Net Cash Flow		5,658	14,697	11,934	12,094	29,074	67,556
Opening net debt/(cash)		84,259	79,537	64,585	54,886	42,488	13,414
Exchange rate movements		0	0	0	0	0	0
Other		(936)	255	(2,235)	304	0	0
Closing net debt/(cash)		79,537	64,585	54,886	42,488	13,414	(54,142)

Source: Edison Investment Research, company accounts. Note: Discontinued operations/minority interest relate to CNS subsidiary Noscira, which was wound up in 2014.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Zeltia and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.